A Pilot Study of 18F-FLT PET/CT in Pediatric Lymphoma

Table 1

Patient characteristics as well as index lesion location, tracer uptake, and reference standard outcome.

Patient	Age, gender	Diagnosis, stage^‡	Index lesion(s) location	18F-FDG SUV	18F-FDG liver SUV	DS	18F-FLT SUV	Reference standard and outcome
1	11, F	HL, IVA	Right subcarinal LN	2.0	1.2	4	3.3	Biopsy, atypical lymphoid hyperplasia
			Retrocaval LN	2.3		4	4.1
2	17, M	HL, IVB	Anterior mediastinal mass	2.2	2.6	3	5.0	Biopsy, thymic tissue
3^†	16, F	HL, IIA	Retroauricular LN	2.5	2.5	3	Nil	Imaging, resolution on follow-up 3 mo 18F-FDG PET/CT
4^†	18, F	HL, IVA	Prevascular LN	3.0	2.4	4	Nil	Imaging, resolution on follow-up 3 mo 18F-FDG PET/CT
			Prevascular LN	3.0		4	Nil
5	17, M	HL, IVA	Lung RUL nodule	2.2	2.3	3	Nil	Imaging, interval decrease in size on 3 mo follow-up chest CT
6	14, M	HL, IIA	Jugulodigastric LN	2.7	2.6	3	2.2	Imaging, resolution on follow-up 3 mo 18F-FDG PET/CT
			Jugulodigastric LN	2.4		3	2.7
			Anterior mediastinal mass	2.6		3	1.7
7^†	15, M	HL, IIV	Posterior cervical LN	2.5	2.4	3	1.7	Imaging, resolution on follow-up 3 mo 18F-FDG PET/CT
			Hilar LN	2.5		3	1.9
			Hilar LN	3.4		4	1.4
8	17, M	DLBCL, I	Jugulodigastric LN	2.9	2.4	4	2.8	Imaging: interval decrease of 18F-FDG uptake on follow-up 3 mo 18F-FDG PET/CT (SUV 1.5)
			Submandibular LN	2.1		3	3.4

Histopathology based on biopsy, when available, or follow-up imaging (i.e., 3-month PET/CT or CT scan) was used as reference standards. HL: Hodgkin lymphoma, DLBCL: diffuse large B-cell lymphoma, SUV: standardized uptake value, LN: lymph node, RUL: right upper lobe, mo: month, and nil: no tracer uptake detected. DS: Deauville score, based on the uptake of 18F-FDG within the index lesion using liver uptake for reference. ^†Patients who were mid chemotherapy at the time of 18F-FLT PET/CT imaging. ^‡All patients with HL were initially diagnosed pathologically with the nodular sclerosing subtype.